PDCD1 and neoplasm: Clear correlation between baseline FT4 (P = 0.001) or M stage (P = 0.015) and short-term tumor response was evident, suggesting that blocking PD-1 with therapeutic antibodies would be useful if patients had a high-level baseline FT4 or earlier M stage.